Literature DB >> 34495449

Exploring the Role of Orexinergic Neurons in Parkinson's Disease.

Sachin Kumar1, Tapan Behl2, Aayush Sehgal1, Sukhbir Singh1, Neelam Sharma1, Saurabh Bhatia3,4, Ahmed Al-Harassi3, Mohammed M Abdel-Daim5,6, Simona Bungau7.   

Abstract

Parkinson's disease (PD) is a neurodegenerative disease affecting about 2% of the population. A neuropeptide, orexin, is linked with sleep abnormalities in the parkinsonian patient. This study aimed to review the changes in the orexinergic system in parkinsonian subjects and the effects of orexin. A number of search techniques were used and presumed during the search, including cloud databank searches of PubMed and Medline using title words, keywords, and MeSH terms. PD is characterised by motor dysfunctions (postural instability, rigidity, tremor) and cognitive disorders, sleep-wake abnormalities grouped under non-motor disorders. The Orexinergic system found in the hypothalamus is linked with autonomic function, neuroprotection, learning and memory, and the sleep-wake cycle. Prepro-orexin, a precursor peptide (130 amino acids), gives rise to orexins (Orx-A and Orx-B). Serum orexin level measurement is vital for evaluating several neurological disorders (Alzheimer's disease, Huntington's disease, and PD). Orexinergic neurons are activated by hypoglycemia and ghrelin, while they are restrained by food consumption and leptin. Orexinergic system dysfunctioning was found to be linked with non-motor symptoms (sleep abnormalities) in PD. Orexinergic neuron's behaviour may be either inhibitory or excitatory depending on the environment in which they are present. As well, orexin antagonists are found to improve the abnormal sleep pattern. Since the orexinergic system plays a role in several psychological and neurological disorders, therefore, these disorders can be managed by targeting this system.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Hypocretin; Narcolepsy; Neuroprotection; Orexin; Orexinergic system; Parkinson’s disease

Mesh:

Substances:

Year:  2021        PMID: 34495449     DOI: 10.1007/s12640-021-00411-4

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  88 in total

1.  Orexin Signaling in the VTA Gates Morphine-Induced Synaptic Plasticity.

Authors:  Corey Baimel; Stephanie L Borgland
Journal:  J Neurosci       Date:  2015-05-06       Impact factor: 6.167

2.  Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia.

Authors:  Paolo Bettica; Lisa Squassante; John A Groeger; Brian Gennery; Raphaelle Winsky-Sommerer; Derk-Jan Dijk
Journal:  Neuropsychopharmacology       Date:  2012-01-11       Impact factor: 7.853

3.  Sleepiness in Idiopathic REM Sleep Behavior Disorder and Parkinson Disease.

Authors:  Isabelle Arnulf; Dulce Neutel; Bastien Herlin; Jean-Louis Golmard; Smaranda Leu-Semenescu; Valérie Cochen de Cock; Marie Vidailhet
Journal:  Sleep       Date:  2015-10-01       Impact factor: 5.849

4.  Sparing of orexin-A and orexin-B neurons in the hypothalamus and of orexin fibers in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated macaques.

Authors:  Manale Bensaid; Dominique Tandé; Véronique Fabre; Patrick P Michel; Etienne C Hirsch; Chantal François
Journal:  Eur J Neurosci       Date:  2014-10-18       Impact factor: 3.386

5.  Sleep inertia measurement with the psychomotor vigilance task in idiopathic hypersomnia.

Authors:  Elisa Evangelista; Anna Laura Rassu; Régis Lopez; Niccolò Biagioli; Sofiène Chenini; Lucie Barateau; Isabelle Jaussent; Yves Dauvilliers
Journal:  Sleep       Date:  2022-01-11       Impact factor: 5.849

6.  Sodium Oxybate for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson Disease: A Randomized Clinical Trial.

Authors:  Fabian Büchele; Marc Hackius; Sebastian R Schreglmann; Wolfgang Omlor; Esther Werth; Angelina Maric; Lukas L Imbach; Stefan Hägele-Link; Daniel Waldvogel; Christian R Baumann
Journal:  JAMA Neurol       Date:  2018-01-01       Impact factor: 18.302

Review 7.  Diagnosis and Treatment of Parkinson Disease: A Review.

Authors:  Melissa J Armstrong; Michael S Okun
Journal:  JAMA       Date:  2020-02-11       Impact factor: 56.272

8.  Ventricular orexin-A (hypocretin-1) levels correlate with rapid-eye-movement sleep without atonia in Parkinson's disease.

Authors:  Agathe Bridoux; Stephane Moutereau; Ala Covali-Noroc; Laurent Margarit; Stephane Palfi; Jean-Paul Nguyen; Jean-Pascal Lefaucheur; Pierre Césaro; Marie-Pia d'Ortho; Xavier Drouot
Journal:  Nat Sci Sleep       Date:  2013-06-12

9.  Cerebrospinal Fluid Hypocretin-1 (Orexin-A) Level Fluctuates with Season and Correlates with Day Length.

Authors:  Kim Boddum; Mathias Hvidtfelt Hansen; Poul Jørgen Jennum; Birgitte Rahbek Kornum
Journal:  PLoS One       Date:  2016-03-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.